HealthDay News — Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published online March ...

Continuing GLP-1 RA use through surgery increases risk for surgical complications including aspiration and conversion to intubation ...

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...

Discontinuation was defined as 60 days without any GLP-1 RA on hand. Reinitiation was defined as the first fill of any GLP-1 RA after discontinuation. Patients were followed for up to two years ...

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to a study ...

Three studies attempting to tease out the potential effects of glucagon-like peptide 1 receptor agonists (GLP-1 RA) taken before or during pregnancy were presented at the annual meeting of the ...

using its long-acting GLP-1 Receptor Agonist [GLP-1 RA] for the treatment of patients with obesity. It is currently in the process of treating obesity patients using the very same drug in an ...

Adults aged 66 years or older with T2D initiating treatment with a GLP-1 RA were propensity score-matched to those initiating treatment with an SGLT-2i (14,665 matched pairs) or a DPP-4i (13,711 ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with type 2 diabetes is linked to a reduced risk of developing certain hematologic cancers compared to insulin and metformin.

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at the annual ...